DALY II Japan/MB-CART2019.1 for DLBCL

DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.

Trial Details

NCT ID
NCT07288879
Phase
PHASE2
Sponsor
Miltenyi Biomedicine GmbH
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • MB-CART2019.1
Locations (sample)
  • Tokyo, Japan|35.6895,139.69171
  • Tokyo, Japan|35.6895,139.69171
  • Tokyo, Japan|35.6895,139.69171
  • Tokyo, Japan|35.6895,139.69171
  • Tokyo, Japan|35.6895,139.69171

Key Eligibility Criteria

  • Histologically confirmed DLBCL or associated subtype, defined by WHO 2016 classification:
  • DLBCL not otherwise specified (NOS)
  • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
  • High-grade B-cell lymphoma, NOS

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →